Notice2025-09932
Foreign-Trade Zone (FTZ) 189, Notification of Proposed Production Activity; Grand River Aseptic Manufacturing; (Pharmaceutical Products); Grand Rapids and Caledonia, Michigan
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
June 2, 2025
Issuing agencies
Commerce DepartmentForeign-Trade Zones Board
Full Text
<html>
<head>
<title>Federal Register, Volume 90 Issue 104 (Monday, June 2, 2025)</title>
</head>
<body><pre>
[Federal Register Volume 90, Number 104 (Monday, June 2, 2025)]
[Notices]
[Page 23310]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2025-09932]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF COMMERCE
Foreign-Trade Zones Board
[B-29-2025]
Foreign-Trade Zone (FTZ) 189, Notification of Proposed Production
Activity; Grand River Aseptic Manufacturing; (Pharmaceutical Products);
Grand Rapids and Caledonia, Michigan
Kent-Ottawa-Muskegon Foreign-Trade Zone Authority, grantee of FTZ
189, submitted a notification of proposed production activity to the
FTZ Board (the Board) on behalf of Grand River Aseptic Manufacturing
(GRAM) for GRAM's facilities in Grand Rapids and Caledonia, Michigan
within FTZ 189. The notification conforming to the requirements of the
Board's regulations (15 CFR 400.22) was received on May 21, 2025.
Pursuant to 15 CFR 400.14(b), FTZ production activity would be
limited to the specific foreign-status material(s)/component(s) and
specific finished product(s) described in the submitted notification
(summarized below) and subsequently authorized by the Board. The
benefits that may stem from conducting production activity under FTZ
procedures are explained in the background section of the Board's
website--accessible via <a href="http://www.trade.gov/ftz">www.trade.gov/ftz</a>.
The proposed finished product is nivolumab (duty-free).
The proposed foreign-status material is atigotatug--nivolumab
(active pharmaceutical ingredient) (duty-free).
Public comment is invited from interested parties. Submissions
shall be addressed to the Board's Executive Secretary and sent to:
<a href="/cdn-cgi/l/email-protection#523426281226203336377c353d24"><span class="__cf_email__" data-cfemail="4e283a340e3a3c2f2a2b60292138">[email protected]</span></a>. The closing period for their receipt is July 14, 2025.
A copy of the notification will be available for public inspection
in the ``Online FTZ Information System'' section of the Board's
website.
For further information, contact Christopher Wedderburn at
<a href="/cdn-cgi/l/email-protection#42012a302b316c1527262627302037302c0236302326276c252d34"><span class="__cf_email__" data-cfemail="90d3f8e2f9e3bec7f5f4f4f5e2f2e5e2fed0e4e2f1f4f5bef7ffe6">[email protected]</span></a>.
Dated: May 28, 2025.
Elizabeth Whiteman,
Executive Secretary.
[FR Doc. 2025-09932 Filed 5-30-25; 8:45 am]
BILLING CODE 3510-DS-P
</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>Indexed from Federal Register on June 2, 2025.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.